CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response

Zupin, Luisa; Polesello, Vania; Alberi, Giulia; Moratelli, Giulia; Croce, Saveria; Masutti, Flora; Pozzato, Gabriele; Crovella, Sérgio; Segat, Ludovica

doi:10.1016/j.molimm.2016.06.009

Cited by 7 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They cloned the CD209 promoter variants and evaluated the promoter activities in a cell model, with the results indicating that CD209 expression was decreased in transfected cells 16 . Another study provided similar evidence to demonstrate that increasing the frequencies of haplotype rs735240 (−939A)‐rs735239 (−871C) in the CD209 promoter was associated with HCV infection 18 . These data suggested that CD209 signaling in dendritic cells might contribute to preventing viral infection.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan

Chan

Wang

Lin

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Single nucleotide polymorphisms (SNPs) in the promoter region of CD209 (cluster of differentiation 209) may influence expression levels, and higher expression of CD209 on immune cells correlate with severity of cartilage destruction in patients with rheumatoid arthritis (RA). Due to the lack of a comprehensive study, this study aimed to investigate the CD209 promoter variants and haplotypes in a Taiwanese population and the association with RA development. Deoxyribonucleic acid (DNA) of peripheral blood mononuclear cells from 126 RA patients and 124 healthy controls was purified, and the CD209 gene promoter was amplified by polymerase chain reaction and analyzed by Sanger sequencing. Results showed that a novel variant −96C>A polymorphism in CD209 promoter was identified in the Taiwanese population, and the frequency was significantly higher in RA patients than in controls (11.51% vs. 2.42%, P < .0001). The odds ratio (OR) for the development of RA was 5.88 (95% CI 2.35–14.74, P < .0001). Other known variants were also evaluated; for instance, −1180 T/T (rs7359874) was increased in RA patients, and the OR for the development of RA was 3.26, 95% CI 0.85–12.52, P = .07). Besides, the haplotype frequencies were calculated; −1180A‐939C‐871 T‐336 T‐139 T‐96A and −1180 T‐939 T‐871C‐336 T‐139C‐96A were increased in RA patients (P = .004 and 0.05, respectively). In summary, CD209‐96A variant could be an important factor for the development of RA in the Taiwanese population.

show abstract

Section: Discussionmentioning

confidence: 88%

“…Several studies proposed that single nucleotide polymorphisms (SNPs) of CD209 promotor sequence are associated with the susceptibility to viral infections, such as dengue virus, human immunodeficiency virus type 1, and hepatitis C virus 16‐18 . These infections may also contribute to the development of RA 19 .…”

Section: Introductionmentioning

confidence: 99%

A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan

Chan

Wang

Lin

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Therefore, both the European guidelines for the diagnosis and treatment of HCV infection and the United States guidelines for the treatment of chronic HCV genotype 1 infection emphasize the use of IL-28b polymorphism to guide and predict the efficacy of PR. In addition, CD209 [ 33 ], IPTA [ 34 ], IL-10 [ 35 ], and other polymorphisms related to the treatment response of the PR regimen are also described. The rs1059369 locus of MIC-1 gene harbors three genotypes: AA, AT, and TT.…”

Section: Discussionmentioning

confidence: 99%

Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C

Chen

Lou

et al. 2021

Mol Cell Biochem

View full text Add to dashboard Cite

The expression of macrophage inhibitory factor-1 (MIC-1) increases in patients with chronic hepatitis C (CHC), but whether MIC-1 level and its polymorphism affect the antiviral efficacy of CHC has not yet been reported. The present study aimed to investigate the association between MIC-1 polymorphism and antiviral efficacy in patients with CHC genotype 1b (CHC 1b). A total of 171 patients with CHC1b were recruited. The polymorphisms of rs1059369 and rs1059519 in MIC-1 were detected by DNA sequencing. All patients received a standard dose of polyethylene glycol interferon + ribavirin (PR regimen), and divided into response, nonresponse, sustained virological response (SVR), and non-sustained virological response (NSVR) groups based on HCV RNA levels. The genotype distribution of the two single nucleotide polymorphisms (SNPs) did not differ between the response and nonresponse groups, SVR and non-SVR groups. However, the level of MIC-1 was positively correlated with ALT, AST, PIIINP, CIV, and HCV RNA (P < 0.05). Compared to before treatment, the level of MIC-1 in plasma was significantly decrease in the response group but not in the non-responsive group. Our results suggest that the level of MIC-1 in CHC1b is correlated with liver cell injury, liver fibrosis index, and viral load. However, the polymorphism of rs1059369 and rs1059519 may have negligible impact in expression of MIC-1 and efficacy of antiviral therapy in CHC patient.

show abstract

“…The CD209 protein has been shown to recognize pathogens through its N-terminal domain, binding to ligands on microbes in the process [25], as well as activating the signal transduction pathway in the process. Since DC's are an essential component for antigen presentation, and for initiation of the process mediating adaptive immune responses, its polymorphisms, especially the rs4804803 (snp -336G/A) gene promoter polymorphism, have been shown to modulate disease susceptibility or severity [26][27][28][29][30][31][32]. We have shown previously that this polymorphism tracks ethnicity, with significant genotypic and allelic diversity between African and American sickle-cell disease patients [27].…”

Section: Introductionmentioning

confidence: 98%

CD209 and Not CD28 or STAT6 Polymorphism Mediates Clinical Malaria and Parasitemia among Children from Nigeria

et al. 2020

View full text Add to dashboard Cite

Malaria remains a significant disease, causing epic health problems and challenges all over the world, especially in sub-Saharan Africa. CD209 and CD28 genes act as co-stimulators and regulators of the immune system, while the STAT6 gene has been reported to mediate cytokine-induced responses. Single nucleotide polymorphisms of these genes might lead to differential disease susceptibility among populations at risk for malaria, due to alterations in the immune response. We aim to identify key drivers of the immune response to malaria infection among the three SNPs: CD209 (rs4804803), CD28 (rs35593994) and STAT6 (rs3024974). After approval and informed consent, we genotyped blood samples from a total of 531 children recruited from Nigeria using the Taqman SNP genotyping assay and performed comparative analysis of clinical covariates among malaria-infected children. Our results reveal the CD209 (rs4804803) polymorphism as a susceptibility factor for malaria infection, significantly increasing the risk of disease among children, but not CD28 (rs35593994) or STAT6 (rs3024974) polymorphisms. Specifically, individuals with the homozygous mutant allele (rs4804803G/G) for the CD209 gene have a significantly greater susceptibility to malaria, and presented with higher mean parasitemia. This observation may be due to a defective antigen presentation and priming, leading to an ineffective downstream adaptive immune response needed to combat infection, as well as the resultant higher parasitemia and disease manifestation. We conclude that the CD209 gene is a critical driver of the immune response during malaria infection, and can serve as a predictor of disease susceptibility or a biomarker for disease diagnosis.

show abstract

CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response

Cited by 7 publications

References 26 publications

A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan

A novel CD209 polymorphism is associated with rheumatoid arthritis patients in Taiwan

Association of macrophage inhibitory factor -1 polymorphisms with antiviral efficacy of type 1b chronic hepatitis C

CD209 and Not CD28 or STAT6 Polymorphism Mediates Clinical Malaria and Parasitemia among Children from Nigeria

Contact Info

Product

Resources

About